FCGR2A and neoplasm: As we demonstrated changes in FcγR on myeloid populations within CPM treated tumors (Figure S6), an Fc-null version of the mAb may prevent it from binding these FcγRs and deleting populations of PD-1+ effector cells via antibody dependent cellular phagocytosis, impairing an anti-tumor immune response (Liu et al., 2020; Dahan et al., 2015; Moreno-Vicente et al., 2022).